Literature DB >> 8886503

Tetrandrine as a calcium antagonist.

H Takemura1, K Imoto, H Ohshika, C Y Kwan.   

Abstract

1. The Ca(2+)-antagonism of tetrandrine (TET) on the Ca2+ mobilization in various types of cells were reviewed. Inositol trisphosphate (IP3)-generating drugs were used as Ca(2+)-mobilizing agonists and the effects were compared with those produced by using the microsomal Ca(2+)-ATPase inhibitor thapsigargin (TG), which is a tool for analysing Ca2+ store-regulated Ca2+ entry (capacitative Ca2+ entry). 2. In rat phaeochromocytoma PC12 cells, 100 mumol/L TET abolished high K+ (30 mmol/L)-induced sustained increases in cytoplasmic Ca2+ concentrations ([Ca2+]i) and partially inhibited bradykinin (1 mumol/L)- or TG (100 nmol/L)-induced Ca2+ entry. 3. In NIH/3T3 fibroblasts and rat parotid acinar cells, 100 mumol/L TET abolished Ca2+ entry induced by bombesin (1 mumol/L) and carbachol (100 mumol/L), respectively, or TG (100 nmol/L). However, in the human leukaemia T cell line Jurkat, 100 mumol/L TET did not inhibit Ca2+ entry evoked by either the anti-CD3 antibody OKT3 (10 mg/L) or TG (100 nmol/L). 4. In rat glioma C6 cells, the effects of TET on Ca2+ mobilization were further examined. At a high concentration, TET (300 mumol/L) alone did not affect [Ca2+]i in C6 cells. Tetrandrine inhibited the peak and sustained increases in [Ca2+]i induced by bombesin and TG in a dose-dependent manner. Although TET or TG did not produce increases in IP3, TET did inhibit increases in IP3 produced by bombesin. 5. Our results suggest that the action of TET on Ca2+ entry is dependent on cell types and that TET inhibits both Ca2+ entry from the extracellular medium and Ca2+ release from intracellular stores in rat glioma C6 cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8886503     DOI: 10.1111/j.1440-1681.1996.tb01772.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  8 in total

Review 1.  Pharmacology of tetrandrine and its therapeutic use in digestive diseases.

Authors:  D G Li; Z R Wang; H M Lu
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

2.  Effects of tetrandrine on glioma cell malignant phenotype via inhibition of ADAM17.

Authors:  Zhichao Wu; Guangzhi Wang; Shaoqian Xu; Yang Li; Yu Tian; Hongshuang Niu; Fei Yuan; Fenggang Zhou; Zhen Hao; Yongri Zheng; Qingsong Li; Jianjiao Wang
Journal:  Tumour Biol       Date:  2013-11-03

3.  Preparation and characterization of tetrandrine-phospholipid complex loaded lipid nanocapsules as potential oral carriers.

Authors:  Yi-qing Zhao; Li-ping Wang; Chao Ma; Kun Zhao; Ying Liu; Nian-ping Feng
Journal:  Int J Nanomedicine       Date:  2013-10-31

Review 4.  Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy.

Authors:  Terry W Moody; Lingaku Lee; Irene Ramos-Alvarez; Tatiana Iordanskaia; Samuel A Mantey; Robert T Jensen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-01       Impact factor: 5.555

5.  Tetrandrine combined with gemcitabine and Cisplatin for patients with advanced non-small cell lung cancer improve efficacy.

Authors:  Wenchao Liu; Ju Zhang; Cheng Ying; Qianrong Wang; Chen Yan; Yang Jingyue; Yu Zhaocai; Xue Yan; Shi Heng-Jun; Jiang Lin
Journal:  Int J Biomed Sci       Date:  2012-03

6.  Self-Nanoemulsifying Drug Delivery System of Tetrandrine for Improved Bioavailability: Physicochemical Characterization and Pharmacokinetic Study.

Authors:  Chunxia Liu; Li Lv; Wei Guo; Lan Mo; Yaoxing Huang; Guocheng Li; Xingzhen Huang
Journal:  Biomed Res Int       Date:  2018-09-27       Impact factor: 3.411

Review 7.  A critical review: traditional uses, phytochemistry, pharmacology and toxicology of Stephania tetrandra S. Moore (Fen Fang Ji).

Authors:  Yueping Jiang; Min Liu; Haitao Liu; Shao Liu
Journal:  Phytochem Rev       Date:  2020-04-24       Impact factor: 5.374

8.  Tetrandrine Suppresses Transient Receptor Potential Cation Channel Protein 6 Overexpression- Induced Podocyte Damage via Blockage of RhoA/ROCK1 Signaling.

Authors:  Jin Yu; Caifeng Zhu; Jiazhen Yin; Dongrong Yu; Feng Wan; Xuanli Tang; Xue Jiang
Journal:  Drug Des Devel Ther       Date:  2020-01-28       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.